{
    "nct_id": "NCT04897594",
    "official_title": "A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)",
    "inclusion_criteria": "* Male or female, 18 to 75 years of age\n* Overweight or obese with a body mass index (BMI) ≥ 25 kg/m2\n* Presumed NASH based on clinical characteristics or prior liver biopsy\n* ALT ≥ 43 IU/L for men and ≥ 28 IU/L for women\n* MRI-cT1 value> 800 ms\n* Written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* History or clinical evidence of chronic liver diseases other than NAFLD\n* History or clinical evidence of cirrhosis, hepatic decompensation or other severe liver impairment\n* History of liver transplant, or current placement on a liver transplant list\n* Weight loss of > 5% total body weight within 3 months prior to Screening\n\nNote: Other protocol-defined inclusion/exclusion criteria could apply.",
    "miscellaneous_criteria": ""
}